April 1, 2009--GlaxoSmithKline today announced the submission of two simultaneous regulatory applications to expand the use of Tyverb/Tykerb® (lapatinib). If authorised, lapatinib could be used as a first-line therapy regimen combined with anti-hormonal therapy for patients with hormone-sensitive, metastatic (or advanced) breast cancer in Europe and the United States.
The details can be read here.
No comments:
Post a Comment